Impact of diabetes mellitus on COVID-19 clinical symptoms and mortality: Jakarta's COVID-19 epidemiological registry. Issue 1 (February 2022)

• Record Type: Journal Article
• Authors: Harbuwono, Dante S.; Handayani, Dwi O.T.L.; Wahyuningsih, Endang S.; Supraptowati, Novita; Ananda, ; Kurniawan, Farid; Wafa, Syahidatul; Kristanti, Melly; Pantoro, Nico I.; Sinto, Robert; Kurniawan, Heri; Rebekka, ; Tahapary, Dicky L.
• Is Part Of: Primary care diabetes. Volume 16:Issue 1(2022)
• Page Start: 65
• Page End: 68
• Publication Date: 2022-02
• Subjects: Clinical symptoms -- COVID-19 -- Diabetes mellitus -- Indonesia -- Mortality; Diabetes -- Periodicals; 616.462
• DOI: 10.1016/j.pcd.2021.11.002
• Languages: English
• ISSNs: 1751-9918

Abstract

Highlights: COVID-19 patient in Jakarta with prior DM were more likely to develop symptoms. DM is independently associated with a higher COVID-19 mortality risk in Jakarta. Hypertension, heart disease, and kidney disease contributed to COVID-19 mortality. Abstract: Background and aims: While the higher prevalence of diabetes mellitus (DM) at younger age in Indonesia might contribute to the relatively higher COVID-19 mortality rate in Indonesia, there were currently no available evidence nor specific policy in terms of COVID-19 prevention and management among DM patients. We aimed to find out the association between diagnosed diabetes mellitus (DM) with COVID-19 mortality in Indonesia. Methods: We performed a retrospective cohort study using Jakarta Province's COVID-19 epidemiological registry within the first 6 months of the pandemic. All COVID-19 confirmed patients, aged >15 years with known DM status were included. Patients were assessed for their clinical symptoms and mortality outcome based on their DM status. A multivariate Cox-regression test was performed to obtain the relative risk (RR) of COVID-19 mortality in the diagnosed DM group. Results: Of 20, 481 patients with COVID-19, 705 (3.4%) had DM. COVID-19 mortality rate in DM group was 21.28%, significantly higher compared to 2.77% mortality in the non-DM group [adjusted RR 1.98 (CI 95% 1.57–2.51), p < 0.001]. In addition, COVID-19 patients with DM generally developed more symptoms. Conclusions: DM is associated not only with development of more COVID-19 clinical symptoms, but also with a higher risk of COVID-19 mortality. This finding may provide a basis for future policy regarding COVID-19 prevention and management among diabetes patients in Indonesia.